The Journal of
Clinical Psychiatry

Psychopharmacology

Podcast November 18, 2025

Leadership in Clinical Psychopharmacology with Dr. Joe Goldberg

Joseph F. Goldberg, MD; Ben Everett, PhD

Listen on your favorite platform

Key Topics Discussed

ASCP’s patient-centered mission and leadership model focused on translating research into practical clinical applications
Task forces providing clinical guidance on ketamine/esketamine use and evidence-based deprescribing practices
AI-enhanced “living textbook” curriculum (edYOU) with continuously updated psychopharmacology content and self-assessment tools
Mentorship pathways and networking opportunities for early career psychiatrists through ASCP committees and the annual meeting
Recent pharmacological advances including treatments for tardive dyskinesia, iatrogenic weight gain, and muscarinic agonists for schizophrenia

Episode Overview

Dr. Joseph Goldberg, Clinical Professor at the Icahn School of Medicine at Mount Sinai and immediate past president of the American Society of Clinical Psychopharmacology (ASCP), shares insights from his remarkable career, from his beginnings in neuroscience to his influential leadership roles. Along the way, he explores the future of mental health, focusing on mentorship, innovative education, and translating research into patient-centered care.

Throughout the episode, Dr. Goldberg recounts his unique journey into psychiatry, which began with studying frogs and led to a focus on bipolar disorder. He offers an insider’s view of the ASCP, detailing initiatives from his presidency, including task forces on ketamine and deprescribing. A key highlight is ASCP’s revolutionary AI-enhanced “living textbook,” a new approach to medical education designed to transform how clinicians learn about psychopharmacology, ensuring the latest knowledge is always accessible.

The Guest

Joseph F. Goldberg, MD, is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and Deputy Editor-in-Chief of The Journal of Clinical Psychiatry. He serves as immediate past president of the American Society of Clinical Psychopharmacology (ASCP), where he has been instrumental in advancing the organization’s mission to translate evidence into patient-centered care. With over 240 peer-reviewed publications and five books, including Clinical Reasoning and Decision-Making in Psychiatry with Dr. Stephen Stahl, Dr. Goldberg is internationally recognized for his work in mood disorders and clinical psychopharmacology.

What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?

Dr. Goldberg discusses ASCP’s groundbreaking task force on deprescribing in this episode. This companion article explores the clinical and linguistic foundations of the term, clarifying when and how psychiatric medications should be discontinued or modified.

READ NOW

Get the latest episodes

The Host

Ben Everett, PhD, is the Senior Scientific Director for The Journal of Clinical Psychiatry and Psychiatrist.com, where he oversees editorial strategy, content development, and multimedia education initiatives. He is the creator and host of The JCP Podcast, a series that brings together leading voices in psychiatry to explore the latest research and its clinical implications. Dr. Everett earned his PhD in Biochemistry with an emphasis in Neuroscience from the University of Tennessee Health Science Center. Over a two-decade career spanning academia, publishing, and the pharmaceutical industry, he has helped launch more than a dozen new treatments across psychiatry, neurology, and cardiometabolic medicine. His current work focuses on translating complex scientific advances into accessible, evidence-based insights that inform clinical practice and foster meaningful dialogue among mental health professionals.

Full Episode Transcript

This transcript has been auto-generated and may contain errors. Please refer to the original recording for full accuracy.

00:00 – Introducing Dr. Joseph Goldberg, MD

Dr Ben Everett (0:01) Hello and welcome to this episode of the JCP podcast. Today I’m honored to be joined by Dr. Joe Goldberg. He is clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai and deputy editor-in-chief of the journal Clinical Psychiatry.

Dr. Goldberg is internationally recognized for his work in mood disorders, particularly bipolar disorder, has authored more than 240 peer-reviewed publications and five books including his latest with Dr. Stephen Stahl called Clinical Reasoning and Decision-Making in Psychiatry. He is distinguished life fellow of the American Psychiatric Association and immediate past president of the American Society of Clinical Psychopharmacology, which we will abbreviate as ASCP. Dr. Goldberg’s career has been defined by his commitment to translating evidence into practical patient-centered care and we’re thrilled to have him on the podcast today.

Dr Joe Goldberg (0:50)

Pleasure’s mine, Ben. Thanks for having me.

01:13 – From Frogs to Psychiatry: A Scientist’s Origin Story

Dr Ben Everett (1:54)

Thank you so much. So we like to start every episode with just a couple of kind of icebreaker questions, a little bit more personal, try and let everybody get to know you. And so really I like to understand, you know, what drew everybody into their into their field of study. So for you, that was medicine.

So it started with medicine. You know, what point in time did you, you know, feel a call to go into medicine?

Dr Joe Goldberg (1:16) Frogs.

Dr Ben Everett (1:17) Frogs?

Dr Joe Goldberg (1:18)

I was in graduate school. I was a psychology major in college and I was I was interested in neuroscience. So I went to graduate school looking biologically and resilience.

And at that time, there were new medicines coming along, medicines that are no longer new. But back in those days, we didn’t have many. So the frogs brought me to med school, brought me to research in psychiatry and psychopharmacology.

And well, here I am today. Excellent.

Dr Ben Everett (1:40)

And then, you know, what was it about, you know, mood disorders, bipolar disorder in particular, that, you know, made that become the focus of your research career and a lot of your clinical practice as well?

02:51 – Why Bipolar Became the Focus: Early Pharmacology Momentum

Dr Joe Goldberg (1:50)

It was kind of an opportune timing for me. So there were, as I mentioned, new drugs coming along, valproate and carbamazepine were pretty brand new at the time. Atypical antipsychotics were just a glimmer on the horizon.

And there wasn’t that much interest in really studying bipolar disorder. In fact, the research group that I affiliated myself with was mainly focusing on psychosis and schizophrenia and mood disorder patients with sort of the comparison group in that research program. Nobody was that interested in them, but I kind of saw this aversion and growth of new pharmacologies.

And it seemed like it was an opportune time to make some inroads in an area that really hadn’t been studied so much before the DSM-3 had just come out. We were just now talking about subtyping bipolar illness into bipolar I and bipolar II and things like rapid cycling. So part of what drew me to this also was there was just so much diversity, I mean, just to talk about elements besides mood, like cognition or cycling frequency or comorbidities or underlying targets.

So I was kind of a scientific kid in a candy store thinking about all these untapped areas that were just becoming of interest. So I just got very interested in the diversity of things that one could study about this up till then, not very extensively exploited research area.

Dr Ben Everett (3:17)

That’s excellent. Thanks for all that. And while this has really been the focus of your career, what we actually want to really get in today is ASCP and your recent tenure as president of the ASCP.

And so really, when or at what point in time did you become interested or drawn to ASCP in particular as a conference? And you might be involved with several conferences. That’s, you know, common too.

04:20 – ASCP’s Patient-Centered Mission & Why It Became “Home”

Dr Joe Goldberg (3:44)

I am. But I have to say at the outset, ASCP has always been my professional home, intellectually, scientifically and socially. All my friends are people at ASCP.

So I was fortunate to have really good mentorship in my psychiatry residency. And there was an organization at the time called NCDEU, the New Clinical Drug Evaluation Unit, that was under the auspices of the NIMH. And that’s an organization that really began in 1959 and was meant to be a coalition of research groups that were just on the precipice of studying new clinical interventions in all of psychiatry.

05:08 – Mentorship Pipeline: NCDEU Roots and Career Breaks

Right around the time of my residency, the NCDU began a new investigator awardee program. I think I was in the second class of new investigator awardees and got invited to go to one of their meetings, which was just eye-opening because it was a chance to meet these sort of luminaries in our field, people like Donald Klein or John Cain, Herb Meltzer, people that were really at the forefront of clinical psychopharmacology over the last decades. It provided mentorship.

It was sort of career guidance. It was sort of semi-apprenticeship. It was shared intellectual interests.

Again, it was just an amazing opportunity for a young psychiatrist in training to get involved and to sort of be put into a position where you can hobnob with people in the know, learn from them, and really expand one’s interest in clinical psychopharmacology. So I’ve been involved with, was NCDEU, and then it became ASCP around about 1992 when the NIMH discontinued its affiliation with the program and the American Society of Clinical Psychopharmacology took over. I had the good fortune of working for John Cain, who was one of the early ASCP presidents, and he really encouraged my further involvement in the organization.

So I joined the board of directors, I forget how many years ago, many years ago. And like I say, really got to sort of see how this organization works in difference from other professional societies. The mission is really patient-oriented care to improve the lives of our patients.

And while a lot of other organizations, I think, have as their mission, the laudable goals of scientific advancement and understanding translational research and breakthrough understandings about basic processes and mental illness, ASCP elevates that beyond that level. It’s really about the pragmatic translation of findings into clinical care, which just really spoke to my interest in the kind of “so what” factor of what it is we do. So I just got hooked early on and I had the good fortune to have a nice run with ASCP.

Dr Ben Everett (6:27)

Yeah, excellent. I can tell you it’s certainly my favorite meeting space as well as a basic science. I love the poster sessions.

There’s always so much late-breaking data and early, you know, phase one, phase two clinical trial reports. You can kind of see what we hope is going to translate all the way through clinical research to new medicines for patients. And so I’ve always enjoyed the meeting as well.

Well, Dr. Goldberg, I know you’ve just finished your term as president of ASCP and now you’re into this immediate past-president stage, which will last two years as your presidency was two years. So this is really great pipeline leadership development program the way ASCP does it. I’m hoping you can speak a little bit about, you know, the leadership of ASCP.

You know, tell us about the new president, some of the new officers.

08:10 – Leadership Model in Action & New President Anita Clayton

Dr Joe Goldberg (7:09)

Yeah, so our model for leadership strives to retain some institutional memory and familiarity with the organization. Our officers derive from our Board of Directors. Our Board of Directors typically derives from people that have been on committees.

People get on committees after being members, so there’s a nice pathway for ascension for anybody who’s interested in leadership roles on a national stage in psychopharmacology. So our incoming president, actually I should say our new president, is Dr. Anita Clayton, a longtime friend. She’s the chairman of psychiatry at the University of Virginia at Richmond.

Her own research for many years has been in sexual functioning and development of new pharmacologies in women’s health. She was very involved with the development of xeranilone, for example. She is our first woman president, yay, so thrilled about that.

And sort of embodies, I think, this model of the clinician, trialist, scientist, someone who sort of gets the basic science aspects, but parlays that into the so-what aspects of clinical care. So she’s very involved in things like FDA regulatory positions about new pharmacologies and the translatability of a scientific or new clinical entity into practical use in real-world patients. So I think she’s going to be a wonderful leader.

She’s spunky, smart, full of energy, and I love to collaborate with her. It’s another nice thing about our leadership model is I think it speaks to, you know, the team approach. We have the longevity of immediate, past, elected positions and current positions.

So the officers work in concert with our board of directors. That’s about 20 individuals. We have some early career psychiatrists in that role as well.

We meet quarterly. So there’s a lot of dialogue and back and forth and input from the board. So that’s a very, very nice model.

It allows for a lot of bouncing off of ideas from one colleague to the next and brainstorming. That’s another way in which I think ASCP’s model is really exemplary for how to run an organization. And then behind Dr. Clayton, Dr. Carlos Zarate, another longtime friend of mine, who’s a section leader at the NIMH, is the new president-elect for ASCP. So the three of us will, I think, work well collaboratively. Matt Macaluso, our treasurer-elect. Dan Iosifescu at NYU is our current treasurer.

And Holly Swartz, my co-resident from back in the day at Payne Whitney, is the immediate past treasurer. So it’s really a team of leaders that oversees the board of directors. And again, our thinking, our directions, our democratic process relies on the input from so many smart, fun, thoughtful colleagues.

It’s just a very nice model to be part of. You know, one of my goals, having had the opportunity to know who’s who in the organization, is to really try to showcase some of the early career people’s interests in particular areas and bring them to the forefront. So I really wanted to make ASCP kind of a household name in clinical psychopharmacology from the standpoint of not just new drug development, but understanding and translation of treatment.

11:17 – ASCP Task Forces: Ketamine/Esketamine and Deprescribing Guidance

Dr Joe Goldberg

Let me give some examples. One of the things I was very happy about during my tenure in the presidency was to develop a series of task forces that were posing particular questions that were very pragmatic and to the point. So one task force that we developed was on the limitations and understanding of ketamine and s-ketamine in clinical psychiatry.

It’s a topic where I think the clinical practice has outpaced the research base. So we convened a task force led by Jerry Sanacora, who’s at Yale. He’s on our board of directors and convened an expert panel of about 20 some odd international experts and really have surveyed their perspectives about the strengths and limitations and pragmatic, again, ways of how to anticipate treatment outcomes with ketamine and s-ketamine, circumstances where it should or shouldn’t be continued.

So really meant it to answer questions. And we’re just finishing up our work on that and hoping to get it for publication. The second task force that we developed, which I felt particularly great affinity to, was with this very controversial topic of deprescribing that’s been in the news lately, in part, I think, because there’s been some misconstrual that the word deprescribing means inappropriate medicines that should be taken away, as opposed to the reevaluation process of whether a given medicine is doing its job and whether or not there’s a better alternative out there.

So we convened on that front, a task force of 47 international psychopharmacology experts asking a whole wide array of questions about circumstances under which a medicine become obsolete or redundant or failing to deliver on its intended promise or whether the adverse effects or tolerability issues outweighed the benefits, things that clinicians, I think, ought to be thinking about intuitively. And we just wanted to make it explicit. So we’ve already published a couple of papers on this, some on just the definition of deprescribing.

We had a symposium and workshop and a poster presentation on it at the annual meeting. And we just sent out the first of several papers with some findings from this Delphi survey of our panelists looking at, again, guidance for practitioners about when to think about timeframes and timelines for when to stop medicines or when to think about changing them. So there’s a couple of other task forces that are in the offing here and subgroups.

And I’m hoping to see those through in my, I guess, post-presidential time. And also drawn in some new people into our fold with interest in exploiting these areas. Dr. David Goodman, who’s at Hopkins, has taken the lead with a deprescribing paper on stimulants. My colleague, Dr. Raj Mago, who’s at Penn. I’ve kindly coerced him into co-leading our CME committee along with its longstanding co-chair, my friend, Dr. Scott Aronson. So they’re also looking to develop some new CME initiatives, which is another area that I think I tried to make a focal point in my tenure.

14:13 – CME 2.0 & AI “Living Textbook” (edYOU) for Psychopharm Education

Dr Joe Goldberg

How do people learn? How do clinicians get new information? On the one hand, nowadays, post-pandemic, there’s been a real plethora of, let’s say, commercially-based CME programming for clinicians.

And that stands alongside what might be called, well, I guess, non-commercially-based CME programming. AICP’s always had a vested interest in impartiality and neutrality and sort of clear-cut science in helping learners understand the best cutting-edge information about psychopharmacology without commercial influence. And so we’ve revamped our CME programming away from more commercial kinds of things into more like case-based learning, online grant rounds, programming that sort of teaches techniques, like we’re developing a CME program on how to evaluate movement disorders and how to differentiate them.

So very much hands on. And then I’d say maybe a crown jewel I might think of from my tenure has been seeing through the development of a new curriculum. So as you know, Ben, our current officer on our board, our treasurer, Dr. Matt Macaluso, along with Dr. Rick Shelton, has taken the lead in developing an entirely new educational curriculum in psychopharmacology, something unlike anything we’ve done before. ASCP pioneered a psychopharmacology curriculum for residents and medical students under Dr. Ira Glick’s aegis for many years. And in sort of passing the torch of that, we’ve now, with Dr. Macaluso and Dr. Shelton, developed not a static presentation style of lectures, but rather an online software program that involves the delivery of state-of-the-art lectures in all aspects of clinical psychopharmacology from beginner to advanced that’s linked to artificial intelligence. So we actually have an AI based teaching assistant that we can call upon in the course of a presentation.

We’ve embedded some videos from some luminaries in our field to sort of make sure people understand where we’ve been. And it’s called a living textbook in psychopharmacology. So it can be continually updated.

People don’t buy a book, they purchase a subscription to a series of lectures that can continually be updated. So we’ve just rolled out the first of those in the last month. It’s our crash course for beginning residents.

And then we’re having a basic course and an advanced course that Matt and Dr. Shelton will be finishing up, I think, by the spring. And it’s going to be a wonderful addition to teaching and education and very state-of-the-art because it’s non-static. It’s a living textbook and we hope it’s going to revolutionize the way we teach psychopharmacology.

Those are a few of the things that I would say, I feel some pride in and what I got to see under my watch.

Dr Ben Everett (16:07)

That sounds great. And I think you should have some pride with all that you’ve accomplished. Yeah, I was at the session where this new virtual AI component, is it called edYOU, like E-D-U, except it’s E-D-Y-O-U.

Dr Joe Goldberg (16:20)

Yes. So indeed we’ve formed a partnership with an educational software organization called edYOU. It’s a company in Los Angeles that’s long been involved in medical education.

Little new to psychiatry, they’ve done a lot more in cardiology and also in medical student education, but they’ve been leaders in the development of software programming and also self-assessment. So one of the ways people learn is by testing themselves. And so edYOU, which is led by a colleague, Dr. Mike Everist, really was very interested in partnering with us to develop this new software program. And so we’re co-collaboratively developing. We’ve done the first of these now, the crash course and the subsequent courses. So we’re very pleased about the chance for this collaboration.

We think it’s going to have wide reach.

Dr Ben Everett (17:07)

Yeah. It really struck me how, you know, educational parameters and the way individuals learn has changed over time and leaning into technology where, we use textbooks and papers, 20, 30, 40 years ago, and now everybody really, you know, they like the video, they like the audio, they like it where, if they need it on their phone, quick access, easy to access, and I can get to it, when I have time to get to it. So I thought it was really good.

18:43 – Limbic Learning & Nasrallah Award: Make Education Stick

Dr Joe Goldberg (17:34)

I’ll add one more thing to this, which is, I have a very strong interest in how people learn psychopharmacology under the very generous auspices of our colleague, Dr. Henry Nasrallah at the University of Cincinnati, who endowed the ASCP, a perpetual grant in his name to establish an annual award for excellence in psychopharmacology education, again, on my watch, great gratitude to Dr. Nasrallah. But so this past year, we did the inaugural Nasrallah award in psychopharmacology teaching and education. And who better than to be our inaugural awardee than Dr. Steve Stahl, he had a wonderful presentation at the ASCP on how to teach psychopharmacology. So to your point, not just about, it can’t be static, it can’t just be, you know, look something up, it’s got to have some dynamic quality to it. And so one of the things that we try to convey in these online virtual software presentations is to keep it lively and engaged and stimulating. So Steve and I both call this limbic learning.

You know, you, you remember things when, when they’re presented with an impactful kind of way, it’s almost like PTSD in reverse and the emotional valence for which you, you learn actually, you know, has some impact. And Steve has just been, I think, exemplary in what I’ll call limbic learning. So we’ve tried to infuse that and impart that in these new lectures.

And I think Steve’s inaugural lecture really sort of drove home that point. If you really want someone to learn something, you’ve got to engage their, their emotional learning processes. It can’t be just cold cognition.

Dr Ben Everett (19:06)

That sounds great. So for, you know, these younger clinicians and researchers, you’ve talked a lot about education, mentorship, how important ASCP was for you in terms of mentorship. What would you say to, you know, young residents, early career psychiatrists, ASCP can offer them in terms of mentorship and in a home, as you said, ASCP was for you.

20:18 – Early-Career Lift: Posters, Committees, New Investigator Awards

Dr Joe Goldberg (19:29)

Yeah. Well, in a word, everything. I mean, if they can come to the annual meeting, if they can submit a poster, if they can apply to the new investigator award program, if they could become part of a committee, like the early career psychiatry committee or the technology committee or the CME committee, we have lots of committees, and get involved.

It is probably the fast track to career elevation and, and the networking. I’ll give you an example. So at the annual meeting, we have mentors.

I was assigned as a mentor to a wonderful young lady who’s doing some research in mood disorders that melds artificial intelligence and a large language processing to make decisions about best treatments. And so she and I were chatting and you meet with your mentor and we’re talking. I started asking her, you know, if, was she familiar with the work of John Rush?

John was the, you know, kind of the architect and pioneer of the STAR*D studies and has done an awful lot with algorithms. And she said, oh, of course I am. I said, well, wait here a second.

And I, I found John, I brought him over and I said, you know, meet John Rush. And the two of them just started talking and, you know, I kind of stepped away cause they got engrossed in conversation. And then, um, it was really productive dialogue the two of them had.

They brainstormed some ideas, talked about some maybe collaborations. And then the next day I’m talking to my mentee about something. She asked a question and I said, oh, well, look, there’s John.

Let’s ask John. And John comes over and I mentioned she had a question and John said, well, I’m sure she can talk for herself, Joe. Thank you.

He excused me. And it was beautiful to see that connection form and those connections happen all the time. Somebody comes by your poster, somebody knows you’re interested in an area of common ground.

They may have some advice for how to network, how to apply for a grant. I mean, it’s just, it’s a wonderful way to have a national reach in your interests to find like-minded colleagues, to brainstorm about projects, papers, ideas, and having had the opportunity to witness this kind of thing for many, many years and having been a recipient on that end many, many years ago myself. I think if I had to pick one thing of value to an early career practitioner who wants to get involved with the organization, it’s this opportunity to sort of hit the ground running, make connections, get inspiration.

And see where it may take your career.

Dr Ben Everett (21:43)

That’s amazing. I love those personal connections and it’s really good stuff. So you’ve covered so much already today.

I just want to know, so what are you most excited or maybe hopeful about when you think about the future of psychopharmacology and psychiatry? And so you’ve got, another year plus two years as you’re in your role as immediate past president, you’re still in this leadership area, you know, what excites you and, and, you know, kind of what’s next. A lot of new stuff that has happened just recently, but, you know, kind of what’s next, what’s this next chapter look like?

23:18 – What’s Next in Psychopharm: Tangible Advances for Patients

Dr Joe Goldberg (22:17)

Well, I don’t know about other areas of medicine, but I know I can say in all honesty to my own patients that we live in a time and an era of true advances. We have things in our pharmacopeia now that did not exist five years ago. We can treat tardive dyskinesia.

We can manage iatrogenic weight gain. We have new ways of treating psychosis in just the last year, muscarinic agonists. So, you know, one of the things I think clinicians, doctors in general, you know, strive to do if nothing else is to maintain and instill a sense of hope in patients, and I can do that with a lot more credibility when I can cite examples like the ones that I just mentioned.

It’s not, it’s not a foofy statement to say, well, let’s see what the future holds. We can say, you know, this is, this is an evolving field. There are true, I don’t want to get hyperbolic with the word breakthroughs, but there are new advances and developments coming.

So an organization like ASCP, I think really means to be at the forefront of that also as a repository of knowledge and information, we like to be very vocal and posting statements on our website and sending out press releases. And if there’s a question that comes up for the population at large, let them ask it of ASCP. We have our experts who are rapidly able to respond to the questions.

We post things on our website. But, you know, that momentum is, is just tremendous. And, again, I, I imagine other fields out there envious of psychiatry, but we have such tangible new developments occurring in ways of thinking about things.

Five of the top 10 leading causes of disability in the world are mental health conditions. And to be able to say we’re in a field where there really truly are meaningful advances that are more than just incremental that can, that can help save lives and improve quality of life and functioning is, is just something enormously special. So I’m very pleased to be in our field at a time when I’m seeing the fruits of all those labors come through.

When I started out right after the frog, we had, you know, glimmers of things that were on the horizon. Now we’ve really got tangible things we can point to and new directions to pursue. And I hope a critical mass of new blood and, and a younger generation clinicians who have the mindset of a clinical trialist, who aren’t just interested in elucidating brain circuits or neurogenesis things like me with the frogs for the sake of knowledge, but how does this make patients’ lives better?

ASCP is the place where that, that can occur. And if I may speak also to the pride with which ASCP has maintained its longstanding relationship with the Journal of Clinical Psychiatry, what better suited peer-reviewed publication than one that is so like-minded in terms of the clinical translatability of scientific findings? When, when, as Deputy Editor-in-Chief, when we look at papers, it’s not just their scientific merit.

It’s, does this speak to a clinical audience? What is a clinical audience going to do with this information? And is a paper properly suited to JCP?

So we hope that our audience identifies as practitioners who want to take new knowledge and put it into play for their patients. So it’s just a wonderful marriage, I think, between ASCP and JCP.

Dr Ben Everett (25:26)

Well, that was going to be my last and final question, and you transitioned right into it. So that, no, no, that was awesome. Um, now look, I really appreciate it.

Is there, you know, anything that you’d like to share with us about ASCP, your, you know, tenure in leadership that continues that we haven’t covered today?

25:44 – ASCP × JCP Synergy & Membership Call to Action

Dr Joe Goldberg (25:46)

Not really. I think just to amplify, uh, for reasons that mystify some of us, it’s not a household name yet. I mean, we have about a thousand, about 1300 members right now.

Our membership at this past, uh, annual meeting in May was, was a record breaker. And, you know, we want to see that grow really, we really want early career practitioners, uh, psychiatrists, uh, PhDs, nurse practitioners, pharmacists. So this is, this is the meeting place, folks.

If you don’t know about ASCP, go to the JCP website or go to the ASCP website. That’s ascpp.org, look through, read about it, join the organization. Hey, you get Jake Lynn’s site for free as a person, as a, as a subscription, a membership is free for residents, but, but then get involved.

And so, you know, I can’t think of a, I’ve been involved with many organizations over the years with APA, with ACNP, with, um, Biological Psychiatry and others, this is a home. This is a place where I think you will find like-minded people. You’ll make friends for life and, um, scientific colleagues.

You can email somebody and say, you know, I was thinking about blah, blah, blah. What do you think of that? So it’s just such a wonderful network and a home environment intellectually and psychologically for people that are interested in the clinical application of psychopharmacology.

Dr Ben Everett (27:01)

Well, I’ll tell you from, from the non-clinical, you know, basic science and translational science standpoint, you know, before coming over to, to JCP and Physicians Postgraduate Press Incorporated, I spent about two decades doing drug development for different pharmaceutical companies, and I love the organization just because of what you spoke to earlier, and that is the translatability of the basic research.

And it’s, it’s the true bench to bedside. You see all that research, and then you go to sessions, you see the clinical pearls and how, you know, the fruits of these basic scientists, you know, years and years ago, how it is paying dividends. And we are seeing tangible, real world benefit to actual patients and to people who don’t do clinical care.

I can, I can tell you it’s very exciting to see that.

27:40 – Looking Ahead: Bridging Bench to Bedside with Future Guests

Dr Joe Goldberg (27:45)

My pledge to listeners would be, if you interact with ASCP or JCP, you will not ask the question, what does this have to do with my patients?

Dr Ben Everett (27:54) Yeah, absolutely. Absolutely.

Dr Joe Goldberg (27:56) It will track.

Dr Ben Everett (27:57)

All right. Well, that’s all we had for today. We’re just starting these, so we’re getting our feet wet a little bit and figuring out how to go about this.

But I want to thank Dr. Goldberg for his time, sharing his perspective on ASCP, your experience in leading the organization. It’s been a great conversation for me. I hope all our listeners enjoy it as well.

We’d love to have you back sometime to dive into your research and clinical world of, you know, bipolar mood disorders and moving beyond the frogs to the actual patients again.

Dr Joe Goldberg (28:27) Anytime.

Dr Ben Everett (28:28)

Thank you. And then I want to invite everybody to join us next time, uh, where my guest is going to be Dr. Steve Brannan. Dr. Brannan is a leading figure in neuroscience drug development. He served as chief medical officer at Karuna Therapeutics, who was responsible for the development of xenamalin trospium.

It’s a novel approach to schizophrenia treatment as the first muscarinic receptor targeting therapy approved for patients with schizophrenia. One of those big new advancements that Dr. Goldberg was just talking about. He has a career that spanned leadership roles at Takeda, Form, Novartis, Eli Lilly, Karuna, among others.

He’ll bring deep insights into full spectrum of CNS drug development from bench to bedside. Again, this topic that we’ve been covering a little bit today. I think you’re not going to want to miss that conversation.

This has been the JCP podcast, insightful, evidence-based human centered. Thanks for joining us until next time. Stay curious, stay informed, and take care.

Dr Joe Goldberg (29:21) Thanks everybody.